Related Experiment Videos
Hemibody irradiation in advanced prostatic carcinoma.
D A Kuban1, P F Schellhammer, A M el-Mahdi
1Eastern Virginia Medical School, Norfolk.
The Urologic Clinics of North America
|February 1, 1991
Summary
Hemibody irradiation offers a safe and effective palliative treatment for bone metastases in advanced prostate cancer. This technique provides rapid pain relief across multiple sites simultaneously, minimizing patient inconvenience and side effects.
Area of Science:
- Oncology
- Radiation Oncology
- Palliative Care
Background:
- Bone metastases are common in advanced prostate cancer, causing significant pain and reduced quality of life.
- Current palliative treatments may have limitations in addressing multiple metastatic sites efficiently.
Purpose of the Study:
- To evaluate hemibody irradiation as a palliative treatment for symptomatic osseous metastases in prostate carcinoma.
- To assess the efficacy, safety, and patient convenience of hemibody irradiation.
Main Methods:
- Hemibody irradiation administered to patients with symptomatic osseous metastases from prostate cancer.
- Adherence to premedication and specific radiation dose guidelines.
Main Results:
- Hemibody irradiation demonstrated safety and efficiency in palliating multiple symptomatic bone metastasis sites.
- Achieved rapid, frequent, and durable pain relief with a single treatment session for multiple areas.
- Side effects, both acute and delayed, were manageable and occurred at a minimal incidence when guidelines were followed.
Conclusions:
- Hemibody irradiation is a pragmatic and appealing palliative option for relieving pain in prostate cancer patients with bone metastases.
- Sequential hemibody radiation showed less dramatic results and considerable complications in prostate cancer.
- Hormonal therapy may be less life-threatening and equally beneficial, but hemibody irradiation remains a valuable palliative choice.